X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA NOVARTIS AJANTA PHARMA/
NOVARTIS
 
P/E (TTM) x 24.5 360.4 6.8% View Chart
P/BV x 10.1 17.7 57.0% View Chart
Dividend Yield % 0.6 1.6 36.5%  

Financials

 AJANTA PHARMA   NOVARTIS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
NOVARTIS
Mar-16
AJANTA PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,720982 175.2%   
Low Rs1,103556 198.3%   
Sales per share (Unadj.) Rs194.6252.9 76.9%  
Earnings per share (Unadj.) Rs45.262.1 72.8%  
Cash flow per share (Unadj.) Rs50.363.3 79.5%  
Dividends per share (Unadj.) Rs8.0010.00 80.0%  
Dividend yield (eoy) %0.61.3 43.6%  
Book value per share (Unadj.) Rs132.0363.6 36.3%  
Shares outstanding (eoy) m88.7731.96 277.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.33.0 238.5%   
Avg P/E ratio x31.212.4 252.2%  
P/CF ratio (eoy) x28.112.2 231.0%  
Price / Book Value ratio x10.72.1 505.4%  
Dividend payout %17.716.1 109.9%   
Avg Mkt Cap Rs m125,29924,580 509.8%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m2,5701,801 142.7%   
Avg. sales/employee Rs ThNM10,748.9-  
Avg. wages/employee Rs ThNM2,395.2-  
Avg. net profit/employee Rs ThNM2,641.1-  
INCOME DATA
Net Sales Rs m17,2758,083 213.7%  
Other income Rs m166829 20.1%   
Total revenues Rs m17,4428,913 195.7%   
Gross profit Rs m5,807234 2,479.6%  
Depreciation Rs m45137 1,227.8%   
Interest Rs m492 2,716.7%   
Profit before tax Rs m5,4741,025 534.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m1,460752 194.1%   
Profit after tax Rs m4,0141,986 202.1%  
Gross profit margin %33.62.9 1,160.2%  
Effective tax rate %26.773.4 36.4%   
Net profit margin %23.224.6 94.6%  
BALANCE SHEET DATA
Current assets Rs m7,63912,678 60.3%   
Current liabilities Rs m2,7152,433 111.6%   
Net working cap to sales %28.5126.7 22.5%  
Current ratio x2.85.2 54.0%  
Inventory Days Days4333 132.2%  
Debtors Days Days7922 349.8%  
Net fixed assets Rs m6,91469 9,991.0%   
Share capital Rs m177160 110.7%   
"Free" reserves Rs m11,44211,460 99.8%   
Net worth Rs m11,72111,621 100.9%   
Long term debt Rs m1490-   
Total assets Rs m14,81414,400 102.9%  
Interest coverage x112.9570.5 19.8%   
Debt to equity ratio x00-  
Sales to assets ratio x1.20.6 207.7%   
Return on assets %27.413.8 198.7%  
Return on equity %34.217.1 200.4%  
Return on capital %46.523.6 197.4%  
Exports to sales %55.10.7 7,404.9%   
Imports to sales %6.018.6 32.3%   
Exports (fob) Rs m9,52760 15,825.7%   
Imports (cif) Rs m1,0381,503 69.0%   
Fx inflow Rs m10,422186 5,594.1%   
Fx outflow Rs m1,6781,821 92.2%   
Net fx Rs m8,744-1,635 -534.9%   
CASH FLOW
From Operations Rs m3,2642,531 129.0%  
From Investments Rs m-2,093-8,270 25.3%  
From Financial Activity Rs m-1,186-386 307.4%  
Net Cashflow Rs m-15-6,125 0.2%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 1.6 2.0 77.5%  
FIIs % 7.6 1.6 475.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 21.5 79.1%  
Shareholders   20,968 41,647 50.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON LTD  FULFORD INDIA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of PNB Fraud, Rising Troubles at PSBs, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed on a negative note yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 236 points and the NSE Nifty closed down by 74 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 19, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - STRIDES SHASUN LTD COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS